- Advanced breast cancer +22005 | Faculty of Medicine in Pilsen, Central Library of Charles University
- Activity of fulvestrant in HER2-overexpressing advanced breast cancer2010 | First Faculty of Medicine
- Vinorelbine, epirubicin, and methotrexate (VEM) as primary treatment in locally advanced breast cancer2001 | Second Faculty of Medicine
- Advanced breast cancer at dpt. of surgery in Pilsen (1998-2002)2002 | Faculty of Medicine in Pilsen
- Radiotherapy in the treatment of advanced breast cancer2014 | Third Faculty of Medicine
- Locally advanced breast cancer in elderly patients2017 | First Faculty of Medicine
- Influence of neoadjuvant chemotherapy on an advanced breast cancer operabilityPublication without faculty affiliation
- Intensive cyclic chemotherapy with unprocessed whole blood support in advanced breast cancer2001 | Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Palliative therapy of advanced breast cancer with targeted polymer-bound drugPublication without faculty affiliation
- First clinical experience with HMPA copolymer-bound doxorubicin in patients with advanced breast cancerPublication without faculty affiliation
- Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses2014 | First Faculty of Medicine
- The use of whole blood rich in PBPC in the haematopoietic support of intensive cyclic chemotherapy used in advanced breast cancer1999 | Faculty of Medicine in Hradec Králové
- Bisphosphonate treatment of bone metastasis improve outcour of systemic treatment of advanced breast cancer2007 | First Faculty of Medicine
- Management of inoperable carcinoma of the breast by curative radiotherapy and chemo-hormonotherapy2001 | Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Final results of an international retrospective observational study in patients with advanced breast cancer treated with oral vinorelbine-based chemotherapy2012 | Faculty of Medicine in Pilsen
- Results of the CONFIRM phase IIItrial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced breast cancer2010 | First Faculty of Medicine
- Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial2014 | First Faculty of Medicine
- Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trial2016 | First Faculty of Medicine
- Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology2013 | First Faculty of Medicine
- Personalization of neo/adjuvant treatment of HER2-positive breast cancer is the key to achieve the best results2022 | First Faculty of Medicine
- Strategies for managing endocrine resistance in advanced hormone receptor-positive and HER2-negative breast cancer2017 | First Faculty of Medicine
- Neoadjuvant chemotherapy with vinorelbine and epirubicine in locallyPublication without faculty affiliation
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. CBYL719C2301Publication without faculty affiliation
- Current perception of neoadjuvant therapy of breast cancer2011 | First Faculty of Medicine
- Current indications for systemic neoadjuvant treatment in breast cancer patients2015 | Publication without faculty affiliation
- Anthracyclines in the treatment of generalized breast cancer2011 | First Faculty of Medicine
- Molecular biology testing in breast cancer2020 | First Faculty of Medicine
- Metastatic Breast Cancer as a Rare Cause of Deafness and Eyesight Deterioration: Case Report2019 | First Faculty of Medicine, Third Faculty of Medicine